<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500993</url>
  </required_header>
  <id_info>
    <org_study_id>Rektum III</org_study_id>
    <nct_id>NCT01500993</nct_id>
  </id_info>
  <brief_title>Capecitabine in the Perioperative Treatment of Rectal Cancer</brief_title>
  <acronym>Rektum-III</acronym>
  <official_title>5-Fluorouracil Versus Capecitabine as Perioperative Treatment for Locally Advanced Rectal Cancer. a Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares capecitabine with standard 5-FU in the perioperative treament of locally
      advanced rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5-Fluorouracil (5-FU) based chemoradiotherapy (CRT) is regarded a standard perioperative
      treatment in locally advanced rectal cancer (LARC). We investigate the replacement of 5-FU by
      the oral pro-drug capecitabine (cape) within a randomized phase III trial. Patients aged ≥18
      years with LARC stage II or III are recruited into this two-arm, two-cohort randomized
      non-inferiority phase-III trial (arm A: cape, arm B: 5-FU; cohort [C] I: adjuvant, C II:
      neoadjuvant). Regimens: Arm A: CRT: 50.4 Gy + cape 1,650 mg/m² days 1-38 plus five cycles of
      cape 2,500 mg/m² d 1-14, repeated d 22 (C I: 2 x cape, CRT, 3 x cape; C II: CRT, TME surgery
      followed by cape x 5). Arm B: CRT: 50.4 Gy + infusional 5-FU 225 mg/m² daily [C I] or
      infusional 5-FU 1,000 mg/m² d 1-5 and 29-33 [C II] plus 4 cycles of bolus 5-FU 500mg/m² d
      1-5, repeated d 29 (C I: 2 x 5-FU, CRT, 2 x 5-FU; C II: CRT, TME surgery followed by 5-FU x
      4). Primary endpoint is 5-year overall survival (OS), secondary endpoints comprise 3-year
      disease-free survival (DFS) and safety.

      The study is designed to investigate whether 5- year overall survival rate (SR5) is
      non-inferior in arm A versus arm B. We hypothesize that SR5 in the standard arm B is 57.5%.
      Sample size calculation is performed with a power of 80% and a type I error of 5% and with a
      drop-out rate of 5%. Therefore, a total of at least 372 evaluable patients (i.e. 186 per arm)
      is required to confirm non-inferiority of the experimental arm A with a non-inferiority
      margin of maximal 12.5% and a median follow-up time of 48 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>3-year DFS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence rate</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of patient with local recurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">401</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>5-Fluorouracil (5-FU)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug - 5FU based chemoradiotherapy and chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug - Capecitabin-based radiochemotherapy and chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)</description>
    <arm_group_label>Capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>4 cycles of bolus 5-FU (500 mg/sqm) and 1 cylce of 5-Fu based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)</description>
    <arm_group_label>5-Fluorouracil (5-FU)</arm_group_label>
    <other_name>5-Fluorouracil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients are 18 years or older and have histologically confirmed
             adenocarcinoma of the rectum (defined as the distal border of the tumour less than 16
             cm from the anal verge measured by rigid rectoscopy) with no evidence of distant
             metastases (identified by abdominal ultrasound or CT scan and chest radiography).

          -  Patients in the adjuvant cohort have undergone R0-resection by total mesorectal
             excision (TME) of a pT3-4 Nany or Tany Npositive non-metastatic rectal cancer.

          -  Patients treated in the neoadjuvant cohort need to have a clinical T3-4 Nany or Tany
             Npositive tumour staged by endoscopic ultrasound, provided the lower border of the
             tumour is located 0 - 16 cm from the anal verge measured by rigid rectoscopy and the
             primary tumour is deemed resectable by TME surgery on the basis of clinical
             assessment. Other eligibility criteria comprise: WHO status of zero or one; adequate
             liver, renal, and bone marrow function defined as follows: leucocyte count &gt; 3,500/µl,
             thrombocyte count &gt; 100,000/µl, hemoglobin &gt; 10.0 g/dl; serum bilirubine &lt; 2.0 mg/dl,
             serum creatinine &lt; 2.0 mg/dl.

        Exclusion criteria:

          -  Prior treatment for rectal cancer, prior chemo- or immunotherapy, prior pelvic
             radiotherapy, or a history of other malignant diseases within the past five years with
             the exception of succesfully treated basal carcinoma of the skin or carcinoma in situ
             of the uterine cervix.

          -  Participation in another trial, pregnancy, breast-feeding, unwillingness to use
             effective contraception, or a medical condition or concomitant illness which could
             potentially interfere with compliance to the protocol are regarded as exclusion
             criteria, as well.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Hofheinz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsmedizin Mannheim Germany, University of Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frederik Wenz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsmedizin Mannheim, Germany, University of Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Post, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsmedizin Mannheim, Germany, University of Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Hochhaus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Jena, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Martina Grunewald</name>
      <address>
        <city>Aschersleben</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Hans Walter Lindemann</name>
      <address>
        <city>Hagen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Hartmut Link</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Elisabeth Fritz</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Stephan Kremers</name>
      <address>
        <city>Lebach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Lothar Müller</name>
      <address>
        <city>Leer</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Christain Constantin</name>
      <address>
        <city>Lemgo</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Erika Kettner</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Markus Moehler</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Udo Hieber</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Ralf Hofheinz</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Matthias Hipp</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof Axel Matzdorff</name>
      <address>
        <city>Saarbrücken</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Stephan Laechelt</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2011</study_first_submitted>
  <study_first_submitted_qc>December 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2011</study_first_posted>
  <last_update_submitted>December 26, 2011</last_update_submitted>
  <last_update_submitted_qc>December 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Frederik Wenz</investigator_full_name>
    <investigator_title>Prof Dr med. F. Wenz</investigator_title>
  </responsible_party>
  <keyword>Rectal cancer</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>phase-III trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

